Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Administration (FDA) on March 4, 2024. About Formosa Pharmaceuticals, Inc.Formosa Pharmaceuticals, Inc. (6838.TWO) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. About TabukEstablished in 1994, Tabuk Pharmaceuticals is a leading Saudi pharmaceutical company with a regional presence in the Middle East and North Africa (MENA). Tabuk Pharmaceuticals reaches patients in 17 countries across the Middle East and North Africa, with future plans to expand its presence in the region. https://www.tabukpharmaceuticals.comView original content to download multimedia:https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-tabuk-pharmaceuticals-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-302139905.htmlSOURCE Formosa Pharmaceuticals Inc.Company Codes: Gretai:6838

Source: The North Africa Journal May 09, 2024 14:04 UTC